Vikram Gota,1 Krunal Kavathiya,1 Kartik Doshi,1 Murari Gurjar,1 Solai E Damodaran,1 Vanita Noronha,2 Amit Joshi,2 Kumar Prabhash2 1Department of Clinical Pharmacology, Advanced Centre for Treatment Research and Education in Cancer, 2Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India Background: Pemetrexed-platinum doublet therapy is a standard treatment for stage IIIb/IV nonsquamous non small cell lung cancer (NSCLC). While the regimen is associated with several grade ≥3 toxicities, hyponatremia is not a commonly reported adverse effect. Here we report an unusually high incidence of grade ≥3 hyponatremia in Indian patients receiving pemetrexed-platinum doublet, and the pharmacological basis for this phenomenon. Met...
Item does not contain fulltextPemetrexed is an important component of first line treatment in patien...
Lung cancer is one of the most common causes in cancer-associated deaths, in which non-small cell lu...
OBJECTIVES: Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based...
High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small ...
Background and Objectives: Hyponatremia is among the most prevalent electrolyte abnormalities observ...
International audienceINTRODUCTION:The small cell lung cancer (SCLC) is a rapidly progressive malign...
Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent that has been shown ...
Pemetrexed is a cytotoxic drug for first-line treatment of lung cancer. It is often combined with ot...
Hyponatremia is the most common electrolyte disorder in lung cancer patients. This condition may be ...
Background: Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiu...
Pemetrexed is an important component of first line treatment in patients with non-squamous non-small...
Pemetrexed is an important component of first line treatment in patients with non-squamous non-small...
Hyponatraemia has been reported with targeted therapies in cancer patients. Aim of the study was to ...
Hyponatraemia has been reported with targeted therapies in cancer patients. Aim of the study was to ...
Shereen Elazzazy,1 Asmaa Elhassan Mohamed,2 Amaal Gulied1 1Pharmacy Department, 2Oncology Hematology...
Item does not contain fulltextPemetrexed is an important component of first line treatment in patien...
Lung cancer is one of the most common causes in cancer-associated deaths, in which non-small cell lu...
OBJECTIVES: Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based...
High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small ...
Background and Objectives: Hyponatremia is among the most prevalent electrolyte abnormalities observ...
International audienceINTRODUCTION:The small cell lung cancer (SCLC) is a rapidly progressive malign...
Background: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent that has been shown ...
Pemetrexed is a cytotoxic drug for first-line treatment of lung cancer. It is often combined with ot...
Hyponatremia is the most common electrolyte disorder in lung cancer patients. This condition may be ...
Background: Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiu...
Pemetrexed is an important component of first line treatment in patients with non-squamous non-small...
Pemetrexed is an important component of first line treatment in patients with non-squamous non-small...
Hyponatraemia has been reported with targeted therapies in cancer patients. Aim of the study was to ...
Hyponatraemia has been reported with targeted therapies in cancer patients. Aim of the study was to ...
Shereen Elazzazy,1 Asmaa Elhassan Mohamed,2 Amaal Gulied1 1Pharmacy Department, 2Oncology Hematology...
Item does not contain fulltextPemetrexed is an important component of first line treatment in patien...
Lung cancer is one of the most common causes in cancer-associated deaths, in which non-small cell lu...
OBJECTIVES: Pemetrexed is indicated for non-small cell lung cancer and mesothelioma. Dosing is based...